Advertisement

Archives of Gynecology and Obstetrics

, Volume 256, Issue 1, pp 1–4 | Cite as

An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases

  • H. -T. Ng
  • C. -C. Yuan
  • Y. -Y. Kan
  • E. S. -C. Ho
  • M. -S. Yen
  • K. -C. Chao
Originals

Abstract

During the past twelve years, out of the 288 cervical cancer patients who had lymph node involvement, the recurrence rate in the lymph node, was 26.6% if one or two nodes were involved and 50.8% if three or more nodes were involved (P<0.0001). The recurrence rate of patients who received eight intravenous treatments (at monthly intervals) of multi-agent chemotherapy was lower than those who did not receive treatment. Of patients with one or two positive lymph nodes, 114 received treatment while 50 did not; their respective recurrence rates were 19.3% and 42.0%, a statistically significant difference (P<0.025). Of patients with three or more positive lymph nodes, 97 received treatment and 27 did not, their respective recurrence rates, were 46% and 66% (P=0.30) and the difference is not statistically significant. It would seem that multi-agent chemotherapy may reduce the recurrence rate in patients with cancer of the cervix and positive lymph nodes.

Key words

Chemotherapy Cervical cancer Lymph node 

Abbreviation

CX CA

Cervival cancer

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tinga DJ, Timmer PR, Bouma J, Salders JG (1990) Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage 1b. Gynecol Oncol 39:1175–1180Google Scholar
  2. 2.
    Ng HT, Shyu SK, Chen YK, Yuan CC, Chao KC, Kan YY (1992) A scoring system for predicting recurrence of cervical cancer. Int J Gynecol Cancer 2:75–78Google Scholar
  3. 3.
    Noguchi H, Shiozawa L, Yoshikimi S (1987) Pelvic lymph node metastasis of uterine cervical cancer. Gynceol Oncol 27:150–158Google Scholar
  4. 4.
    Firedlander M, Kaye SB, Sullian A, Atkinsion K, Elliot P, Coppleson M, Houghton R, Solomon J, Greed D, Russell P, Hudson CN, Langlands AO, Tattersall MAN (1983) Cerevical carcinoma: A drug responsive tumor-experience with combined cisplatin, vinblastin, and bleomycin therapy. Gynecol Oncol 16:275–281Google Scholar
  5. 5.
    Wertheim MS, Hakes TB, Dalghestani AN, Nori D, Smith DH, Lewis JL (1985) A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. J Chin Oncol 3:912–916Google Scholar
  6. 6.
    Ng HT, Kan YY, Chao KC (1987) The outcome of the patients with recurrent cervical carcinoma in terms of lymph node metastasis and treatment. Gynecol Oncol 26:355–363Google Scholar
  7. 7.
    Dargent D, Frobert JL, Beau G (1985) V factor (tumor volume) and T factor (FIGO Classification) in the assessment of cervix cancer prognosis: the risk of lymph node spread. Gynecol Oncol 22:15–22Google Scholar
  8. 8.
    Larrsen G, Alm P, Gallberg B, Grundsell H (1985) Prognostic factors in early invasive carcinoma of the uterine cervix. Am J Obstet Gynecol 146:145–153Google Scholar
  9. 9.
    Burghardt E, Pickel H, Hass J, Lahousen M (1987) Prognostic factors and operation treatment of stage lb or 2b cervical cancer. Am J Obstet Gynecol 156:988–996Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • H. -T. Ng
    • 1
  • C. -C. Yuan
    • 1
  • Y. -Y. Kan
    • 1
  • E. S. -C. Ho
    • 1
  • M. -S. Yen
    • 1
  • K. -C. Chao
    • 1
  1. 1.Department of Obstetrics & Gynecology, National Yang-Ming Medical CollegeVeterans General HospitalTaiwan, Republic of China

Personalised recommendations